Literature DB >> 21982220

Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16.

Craig D Woodworth1, Laura P Diefendorf, David F Jette, Abdulmajid Mohammed, Michael A Moses, Sylvia A Searleman, Dan A Stevens, Katelynn M Wilton, Sumona Mondal.   

Abstract

The Human Papillomavirus type-16 (HPV-16) E6 and E7 oncogenes are selectively retained and expressed in cervical carcinomas, and expression of E6 and E7 is sufficient to immortalize human cervical epithelial cells. Expression of the epidermal growth factor receptor (EGFR) is often increased in cervical dysplasia and carcinoma, and HPV oncoproteins stimulate cell growth via the EGFR pathway. We found that erlotinib, a specific inhibitor of EGFR tyrosine kinase activity, prevented immortalization of cultured human cervical epithelial cells by the complete HPV-16 genome or the E6/E7 oncogenes. Erlotinib stimulated apoptosis in cells that expressed HPV-16 E6/E7 proteins and induced senescence in a subpopulation of cells that did not undergo apoptosis. Since immortalization by HPV E6/E7 is an important early event in cervical carcinogenesis, the EGFR is a potential target for chemoprevention or therapy in women who have a high risk for cervical cancer. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21982220      PMCID: PMC3208720          DOI: 10.1016/j.virol.2011.09.014

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  49 in total

1.  Glucocorticoids stimulate growth of human papillomavirus type 16 (HPV16)-immortalized human keratinocytes and support HPV16-mediated immortalization without affecting the levels of HPV16 E6/E7 mRNA.

Authors:  M A Khan; A J Canhoto; P R Housley; K E Creek; L Pirisi
Journal:  Exp Cell Res       Date:  1997-10-10       Impact factor: 3.905

Review 2.  Chemoprevention of cervical cancer.

Authors:  Peter Sasieni
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2006-01-04       Impact factor: 5.237

Review 3.  Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies.

Authors:  Ami P Vaidya; Aric D Parnes; Michael V Seiden
Journal:  Curr Treat Options Oncol       Date:  2005-03

4.  Tyrphostins that suppress the growth of human papilloma virus 16-immortalized human keratinocytes.

Authors:  H Ben-Bassat; S Rosenbaum-Mitrani; Z Hartzstark; R Levitzki; M Chaouat; Z Shlomai; B Y Klein; N Kleinberger-Doron; A Gazit; R Tsvieli; A Levitzki
Journal:  J Pharmacol Exp Ther       Date:  1999-09       Impact factor: 4.030

Review 5.  Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.

Authors:  Janine Smith
Journal:  Clin Ther       Date:  2005-10       Impact factor: 3.393

6.  Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment.

Authors:  Craig D Woodworth; Evan Michael; Dan Marker; Sarah Allen; Laura Smith; Matthias Nees
Journal:  Mol Cancer Ther       Date:  2005-04       Impact factor: 6.261

7.  Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis.

Authors:  A M Kersemaekers; G J Fleuren; G G Kenter; L J Van den Broek; S M Uljee; J Hermans; M J Van de Vijver
Journal:  Clin Cancer Res       Date:  1999-03       Impact factor: 12.531

Review 8.  The ErbB receptors and their ligands in cancer: an overview.

Authors:  N Normanno; C Bianco; L Strizzi; M Mancino; M R Maiello; A De Luca; F Caponigro; D S Salomon
Journal:  Curr Drug Targets       Date:  2005-05       Impact factor: 3.465

9.  Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogene.

Authors:  Sybil M Genther Williams; Gary L Disbrow; Richard Schlegel; Daekee Lee; David W Threadgill; Paul F Lambert
Journal:  Cancer Res       Date:  2005-08-01       Impact factor: 12.701

10.  Human papillomavirus type 16 E7 protein sensitizes cervical keratinocytes to apoptosis and release of interleukin-1alpha.

Authors:  M Iglesias; K Yen; D Gaiotti; A Hildesheim; M H Stoler; C D Woodworth
Journal:  Oncogene       Date:  1998-09-10       Impact factor: 9.867

View more
  8 in total

1.  A pervasive role for MIG6 in restraining cell proliferation.

Authors:  S Anastasi; L Castellani; S Alemà; O Segatto
Journal:  Cell Death Differ       Date:  2013-12-20       Impact factor: 15.828

2.  Selective permeabilization of cervical cancer cells to an ionic DNA-binding cytotoxin by activation of P2Y receptors.

Authors:  Maurish Bukhari; Han Deng; Noelle Jones; Zachary Towne; Craig D Woodworth; Damien S K Samways
Journal:  FEBS Lett       Date:  2015-05-01       Impact factor: 4.124

Review 3.  The Interaction Between Human Papillomaviruses and the Stromal Microenvironment.

Authors:  B Woodby; M Scott; J Bodily
Journal:  Prog Mol Biol Transl Sci       Date:  2016-10-11       Impact factor: 3.622

4.  Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines.

Authors:  Ingrid Fumagalli; Delphine Dugue; Jean Emmanuel Bibault; Céline Clémenson; Marie Catherine Vozenin; Michele Mondini; Eric Deutsch
Journal:  Onco Targets Ther       Date:  2015-02-02       Impact factor: 4.147

Review 5.  The Role of Kinase Modulators in Cellular Senescence for Use in Cancer Treatment.

Authors:  Chang Sup Lee; Juhwa Baek; Sun-Young Han
Journal:  Molecules       Date:  2017-08-25       Impact factor: 4.411

6.  The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy.

Authors:  Ji Young Choi; Miso Kim; Bhumsuk Keam; Tae Min Kim; Dong-Wan Kim; Dae Seog Heo; Seong Jin Jo
Journal:  Cancer Res Treat       Date:  2018-04-05       Impact factor: 4.679

Review 7.  Emerging biological treatments for uterine cervical carcinoma.

Authors:  Patrizia Vici; Luciano Mariani; Laura Pizzuti; Domenico Sergi; Luigi Di Lauro; Enrico Vizza; Federica Tomao; Silverio Tomao; Emanuela Mancini; Cristina Vincenzoni; Maddalena Barba; Marcello Maugeri-Saccà; Giuseppe Giovinazzo; Aldo Venuti
Journal:  J Cancer       Date:  2014-01-05       Impact factor: 4.207

8.  Altered Expression of Three EGFR Posttranslational Regulators MDGI, MIG6, and EIG121 in Invasive Breast Carcinomas.

Authors:  Didier Meseure; Kinan Drak Alsibai; Sophie Vacher; Rana Hatem; Andre Nicolas; Celine Callens; Florence Lerebours; Ivan Bieche
Journal:  Anal Cell Pathol (Amst)       Date:  2020-04-20       Impact factor: 2.916

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.